ICAM1 and acute lymphoblastic leukemia: Notably, blockade of ICAM-1 and/or VCAM-1 in leukemic mice, or downstream FAK/PYK2 pathways, significantly diminishes T-ALL burden in multiple organs and confers a significant survival benefit in leukemic mice.